- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Big Foodies
Global Pharmaceuticals & Biotech Big Foodies
UPDATED Mar 12, 2024
If you loved that 'dish' and believe the whole world would like it, this list's for you.
1,260 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| INCYIncyte | US$59.33 | 0.7% | -19.8% | US$13.6b | US$76.10 | PE22.3x | E20.2% | n/a | ||
| BMYBristol-Myers Squibb | US$54.40 | 5.0% | -18.2% | US$109.9b | US$55.25 | PE13.7x | E7.6% | 4.4% | ||
| AMPHAmphastar Pharmaceuticals | US$44.15 | -6.7% | 18.7% | US$2.1b | US$64.80 | PE15.4x | E19.3% | n/a | ||
| PNTPOINT Biopharma Global | US$12.50 | 0.2% | 75.1% | US$1.3b | US$12.50 | PE13.8x | E9.2% | n/a | ||
| CORTCorcept Therapeutics | US$24.46 | 5.5% | 15.8% | US$2.5b | US$42.80 | PE24x | E26.2% | n/a | ||
| RPRXRoyalty Pharma | US$30.35 | 3.1% | -8.6% | US$18.0b | US$45.40 | PE11.9x | E5.9% | 2.8% | ||
| GILDGilead Sciences | US$75.08 | 2.9% | -5.9% | US$93.8b | US$87.32 | PE16.5x | E6.5% | 4.1% | ||
| NBIXNeurocrine Biosciences | US$137.74 | 3.0% | 44.3% | US$13.8b | US$150.36 | PE54.9x | E26.5% | n/a | ||
| OCUPOcuphire Pharma | US$2.14 | -11.9% | -42.6% | US$51.9m | US$20.50 | PS2.8x | E8.0% | n/a | ||
| TGTXTG Therapeutics | US$15.84 | -12.4% | 6.5% | US$2.4b | US$29.75 | PE181x | E49.9% | n/a | ||
| PCRXPacira BioSciences | US$30.56 | 3.8% | -22.0% | US$1.4b | US$45.73 | PE33.9x | E29.3% | n/a | ||
| BMRNBioMarin Pharmaceutical | US$85.18 | -1.0% | -5.6% | US$16.2b | US$109.83 | PE95.9x | E30.6% | n/a | ||
| PLXProtalix BioTherapeutics | US$1.43 | -5.9% | -28.1% | US$105.1m | US$13.00 | PE9.8x | E84.7% | n/a | ||
| JNJJohnson & Johnson | US$162.74 | 1.7% | 5.7% | US$388.4b | US$174.42 | PE29.4x | E9.7% | 2.9% | ||
| MRKMerck | US$122.66 | -0.1% | 14.7% | US$310.9b | US$134.16 | PE851.1x | E23.7% | 2.5% | ||
| ZTSZoetis | US$181.35 | -2.1% | 10.2% | US$84.0b | US$221.93 | PE35.4x | E8.1% | 1.0% | ||
| HRMYHarmony Biosciences Holdings | US$30.42 | -1.1% | -26.7% | US$1.7b | US$41.63 | PE13.4x | E25.8% | n/a | ||
| VRTXVertex Pharmaceuticals | US$412.45 | -0.7% | 39.7% | US$107.1b | US$459.98 | PE29.4x | E11.2% | n/a | ||
| PRGOPerrigo | US$30.55 | 12.1% | -14.9% | US$4.1b | US$38.75 | PB0.9x | E47.2% | 3.6% | ||
| EXELExelixis | US$22.69 | 1.9% | 29.9% | US$6.8b | US$26.63 | PE33.1x | E23.3% | n/a | ||
| SCYXSCYNEXIS | US$1.60 | -3.0% | 22.1% | US$59.9m | US$7.13 | PE0.8x | E-23.3% | n/a | ||
| UTHRUnited Therapeutics | US$246.87 | 7.4% | 11.9% | US$11.7b | US$287.02 | PE11.8x | E7.6% | n/a | ||
| PBSVPharma-Bio Serv | US$0.89 | -1.1% | -22.6% | US$20.7m | n/a | PE15.6x | n/a | 25.3% | ||
| KRYSKrystal Biotech | US$178.95 | 4.7% | 142.5% | US$4.8b | US$185.90 | PE463.1x | E43.4% | n/a |